Dana Leone

After market close on Wednesday, bluebird bio Inc (NASDAQ: BLUE) released early data on the relapsed/refractory multiple myeloma study. Traders flocked to the stock after the good news, and the stock was up 22 percent after hours, spiking to $74.45 at market open Thursday, before leveling out at $...

BTIG analyst Dane Leone likes Johnson & Johnson (NYSE: JNJ) and for good reason. Shares of the pharmaceutical firm have gained just over 11 percent year-to-date. The recent plateau in price appreciation, though, has broken Leone's conviction for a Buy recommendation. After the market...